Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions.

Clappier E, Auclerc MF, Rapion J, Bakkus M, Caye A, Khemiri A, Giroux C, Hernandez L, Kabongo E, Savola S, Leblanc T, Yakouben K, Plat G, Costa V, Ferster A, Girard S, Fenneteau O, Cayuela JM, Sigaux F, Dastugue N, Suciu S, Benoit Y, Bertrand Y, Soulier J, Cavé H.

Leukemia. 2014 Jan;28(1):70-7. doi: 10.1038/leu.2013.277. Epub 2013 Sep 25.

PMID:
24064621
2.

IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.

Clappier E, Grardel N, Bakkus M, Rapion J, De Moerloose B, Kastner P, Caye A, Vivent J, Costa V, Ferster A, Lutz P, Mazingue F, Millot F, Plantaz D, Plat G, Plouvier E, Poirée M, Sirvent N, Uyttebroeck A, Yakouben K, Girard S, Dastugue N, Suciu S, Benoit Y, Bertrand Y, Cavé H; European Organisation for Research and Treatment of Cancer, Children's Leukemia Group (EORTC-CLG).

Leukemia. 2015 Nov;29(11):2154-61. doi: 10.1038/leu.2015.134. Epub 2015 Jun 8.

PMID:
26050650
3.

The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013.

Olsson L, Ivanov Öfverholm I, Norén-Nyström U, Zachariadis V, Nordlund J, Sjögren H, Golovleva I, Nordgren A, Paulsson K, Heyman M, Barbany G, Johansson B.

Br J Haematol. 2015 Sep;170(6):847-58. doi: 10.1111/bjh.13514. Epub 2015 May 27.

PMID:
26018335
4.

Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study.

Boer JM, van der Veer A, Rizopoulos D, Fiocco M, Sonneveld E, de Groot-Kruseman HA, Kuiper RP, Hoogerbrugge P, Horstmann M, Zaliova M, Palmi C, Trka J, Fronkova E, Emerenciano M, do Socorro Pombo-de-Oliveira M, Mlynarski W, Szczepanski T, Nebral K, Attarbaschi A, Venn N, Sutton R, Schwab CJ, Enshaei A, Vora A, Stanulla M, Schrappe M, Cazzaniga G, Conter V, Zimmermann M, Moorman AV, Pieters R, den Boer ML.

Leukemia. 2016 Jan;30(1):32-8. doi: 10.1038/leu.2015.199. Epub 2015 Jul 23.

PMID:
26202931
5.

IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan.

Asai D, Imamura T, Suenobu S, Saito A, Hasegawa D, Deguchi T, Hashii Y, Matsumoto K, Kawasaki H, Hori H, Iguchi A, Kosaka Y, Kato K, Horibe K, Yumura-Yagi K, Hara J, Oda M; Japan Association of Childhood Leukemia Study (JACLS).

Cancer Med. 2013 Jun;2(3):412-9. doi: 10.1002/cam4.87. Epub 2013 May 9.

6.

Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia.

Caye A, Beldjord K, Mass-Malo K, Drunat S, Soulier J, Gandemer V, Baruchel A, Bertrand Y, Cavé H, Clappier E.

Haematologica. 2013 Apr;98(4):597-601. doi: 10.3324/haematol.2012.073965. Epub 2012 Oct 12.

7.

IKZF1 and CRLF2 gene alterations correlate with poor prognosis in Japanese BCR-ABL1-negative high-risk B-cell precursor acute lymphoblastic leukemia.

Yamashita Y, Shimada A, Yamada T, Yamaji K, Hori T, Tsurusawa M, Watanabe A, Kikuta A, Asami K, Saito AM, Horibe K.

Pediatr Blood Cancer. 2013 Oct;60(10):1587-92. doi: 10.1002/pbc.24571. Epub 2013 Jun 27.

PMID:
23804397
8.

Ikaros and leukaemia.

Olsson L, Johansson B.

Br J Haematol. 2015 May;169(4):479-91. doi: 10.1111/bjh.13342. Epub 2015 Mar 5. Review.

PMID:
25753742
9.

Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.

Scheijen B, Boer JM, Marke R, Tijchon E, van Ingen Schenau D, Waanders E, van Emst L, van der Meer LT, Pieters R, Escherich G, Horstmann MA, Sonneveld E, Venn N, Sutton R, Dalla-Pozza L, Kuiper RP, Hoogerbrugge PM, den Boer ML, van Leeuwen FN.

Haematologica. 2017 Mar;102(3):541-551. doi: 10.3324/haematol.2016.153023. Epub 2016 Dec 15.

10.

ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia.

Zaliova M, Zimmermannova O, Dörge P, Eckert C, Möricke A, Zimmermann M, Stuchly J, Teigler-Schlegel A, Meissner B, Koehler R, Bartram CR, Karawajew L, Rhein P, Zuna J, Schrappe M, Cario G, Stanulla M.

Leukemia. 2014 Jan;28(1):182-5. doi: 10.1038/leu.2013.282. Epub 2013 Sep 27. No abstract available. Erratum in: Leukemia. 2015 May;29(5):1222.

PMID:
24072102
11.

[Significance of ikaros family zinc finger 1 deletion in pediatric B-acute lymphoblastic leukemia without reproducible cytogenetic abnormalities].

Liu X, Zhang L, Zou Y, Chang L, Wei W, Ruan M, Chen Y, Yang W, Chen X, Guo Y, Wang S, Liu T, Zhang J, Liu F, Qi B, An W, Zhu X.

Zhonghua Er Ke Za Zhi. 2016 Feb;54(2):126-30. doi: 10.3760/cma.j.issn.0578-1310.2016.02.011. Chinese.

PMID:
26875463
12.

High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia.

Vendramini E, Giordan M, Giarin E, Michielotto B, Fazio G, Cazzaniga G, Biondi A, Silvestri D, Valsecchi MG, Muckenthaler MU, Kulozik AE, Gattei V, Izraeli S, Basso G, Te Kronnie G.

Oncotarget. 2017 Jun 27;8(26):42398-42413. doi: 10.18632/oncotarget.16392.

13.

IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: a multicenter analysis in Taiwan.

Yang YL, Hung CC, Chen JS, Lin KH, Jou ST, Hsiao CC, Sheen JM, Cheng CN, Wu KH, Lin SR, Yu SL, Chen HY, Lu MY, Wang SC, Chang HH, Lin SW, Su YN, Lin DT.

Cancer Sci. 2011 Oct;102(10):1874-81. doi: 10.1111/j.1349-7006.2011.02031.x. Epub 2011 Aug 12.

14.

CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol.

Ghazavi F, Clappier E, Lammens T, Suciu S, Caye A, Zegrari S, Bakkus M, Grardel N, Benoit Y, Bertrand Y, Minckes O, Costa V, Ferster A, Mazingue F, Plat G, Plouvier E, Poirée M, Uyttebroeck A, van der Werff-Ten Bosch J, Yakouben K, Helsmoortel H, Meul M, Van Roy N, Philippé J, Speleman F, Cavé H, Van Vlierberghe P, De Moerloose B.

Haematologica. 2015 Oct;100(10):1311-9. doi: 10.3324/haematol.2015.126953. Epub 2015 Jul 2.

15.

IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.

Kuiper RP, Waanders E, van der Velden VH, van Reijmersdal SV, Venkatachalam R, Scheijen B, Sonneveld E, van Dongen JJ, Veerman AJ, van Leeuwen FN, van Kessel AG, Hoogerbrugge PM.

Leukemia. 2010 Jul;24(7):1258-64. doi: 10.1038/leu.2010.87. Epub 2010 May 6.

PMID:
20445578
16.

What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?

Palmi C, Valsecchi MG, Longinotti G, Silvestri D, Carrino V, Conter V, Basso G, Biondi A, Kronnie GT, Cazzaniga G.

Haematologica. 2013 Aug;98(8):1226-31. doi: 10.3324/haematol.2012.075432. Epub 2013 Apr 12.

17.

Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features.

Schwab CJ, Chilton L, Morrison H, Jones L, Al-Shehhi H, Erhorn A, Russell LJ, Moorman AV, Harrison CJ.

Haematologica. 2013 Jul;98(7):1081-8. doi: 10.3324/haematol.2013.085175. Epub 2013 Mar 18.

18.

[Significance of IKZF1 gene copy number abnormalities in BCR/ABL-negative B-lineage acute lymphoblastic leukemia in children].

Zou Y, Liu XM, Zhang L, Chen YM, Guo Y, Chen XJ, Yang WY, Wang SC, Ruan M, Liu TF, Zhang JY, Liu F, Qi BQ, Zhu XF.

Zhongguo Dang Dai Er Ke Za Zhi. 2015 Nov;17(11):1154-9. Chinese.

19.
20.

COBL is a novel hotspot for IKZF1 deletions in childhood acute lymphoblastic leukemia.

Lopes BA, Meyer C, Barbosa TC, Zur Stadt U, Horstmann M, Venn NC, Heatley S, White DL, Sutton R, Pombo-de-Oliveira MS, Marschalek R, Emerenciano M.

Oncotarget. 2016 Aug 16;7(33):53064-53073. doi: 10.18632/oncotarget.10590.

Supplemental Content

Support Center